Multiple Sclerosis Clinical Trial

Avonex 15 Year Long Term Follow-up Study

Summary

The Avonex Fifteen-year Long-term Follow-up of Patients with Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs (ASSURANCE), was a single-time-point evaluation of patients conducted 15 years after the pivotal MSCRG study, evaluated the impact of IM IFNβ-1a treatment on long-term disability and Quality of Life outcomes in patients who completed 2 years in a previous Multiple Sclerosis Collaborative Research Group (MSCRG) study.

View Full Description

Full Description

The primary objective of this study is to determine the impact of early versus delayed initiation of treatment on the long-term physical status of patients with relapsing forms of MS measured by the self-reported EDSS.

Primary endpoints for this study were as follows:

Changes in EDSS score from baseline for original Avonex® pivotal trial
Percentage of patients with EDSS scores less than or equal to 4
Percentage of patients with EDSS scores less than or equal to 6
Percentage of patients with EDSS scores less than or equal to 7

Secondary endpoints were:

Percentage of patients alive
Percentage of patients living independently
SF 36 Quality of Life status
Self-reported VAS of independence with self-care

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients having completed at least 2 years of treatment (Avonex® or placebo) in the original Avonex® pivotal trial.
Subjects (or their caregivers) must be willing to complete a multi-page questionnaire.
Signed written informed consent form

Exclusion Criteria:

Unwillingness or inability to comply with the requirements of this protocol.
Any other reasons that, in the opinion of the Investigator, the subject is determined to be unsuitable for enrollment into this study

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

122

Study ID:

NCT00525343

Recruitment Status:

Completed

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

Georgetown University Medical Center
Washington District of Columbia, 20007, United States
Jocab's Neurological Institute
Buffalo New York, 14203, United States
Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
Oregon Health and Science University
Portland Oregon, 97239, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

122

Study ID:

NCT00525343

Recruitment Status:

Completed

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider